Vimarsana
Biggest News Aggregation in the World

Page 10 - Ir Team News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ir Team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ir Team Today - Breaking & Trending Today

Junshi Biosciences Announces Toripalimab in Combination - Vimarsana News

Junshi Biosciences Announces Toripalimab in Combination

SHANGHAI, China, Feb. 20, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced...

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - Vimarsana News

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Announces Changes to Board of Directors - Vimarsana News

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Announces Changes to Board of Directors

Investegate announcements from Etalon Group PLC, Etalon Announces Changes to Board of Directors

Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma - Vimarsana News

Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

- Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with toripalimab plus chemotherapy significantly prolongs survival in patients with advanced NPC - SHANGHAI, China

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Group Operating Results for FY and 4Q 2022 - Vimarsana News

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Group Operating Results for FY and 4Q 2022

Investegate announcements from Etalon Group PLC, Etalon Group Operating Results for FY and 4Q 2022